Treatment of human papillomavirus (HPV) type 16-infected cells using herpes simplex virus type 1 thymidine kinase-mediated gene therapy transcriptionally regulated by the HPV E2 protein

Human Gene Therapy

Volumn 14, Issue 1, 2003, Pages 45-57

  Sethi, Neerja ^a,b   Palefsky, Joel ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; GANCICLOVIR; HERPES SIMPLEX VIRUS TYPE 1 THYMIDINE KINASE; HUMAN PAPILLOMA VIRUS E2 PROTEIN; NUCLEOTIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL LINE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PLASMID; PROMOTER REGION; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; CELLS, CULTURED; DNA-BINDING PROTEINS; DOGS; FLUORESCENT ANTIBODY TECHNIQUE; GANCICLOVIR; GENE THERAPY; HERPESVIRUS 1, HUMAN; HUMANS; LUCIFERASES; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHOSPHORYLATION; PRODRUGS; PROMOTER REGIONS (GENETICS); THYMIDINE KINASE; TRANSCRIPTION, GENETIC; UP-REGULATION;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 1; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; PAPOVAVIRIDAE; SIMPLEXVIRUS;

EID: 0037251520     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340360464705     Document Type: Article

References (55)

1. ALLOUL, N., and SHERMAN, L. (1992). The E2 protein of human papillomavirus type 16 is translated from a variety of differentially spliced polycistronic mRNAs. J. Gen. Virol. 80, 29-37.
2. ANDERSON, W.F. (1998). Human gene therapy. Nature 392(Suppl.), 25-30.
3. BAKER, C.C., PHELPS, W.C., LINDGREN, V., BRAUN, M.J., GONDA, M.A., and HOWLEY, P.M. (1987). Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J. Virol. 61, 962-971.
4. BAUER-HOFFMAN, R., BORGHOUTS, C., AUVINEN, E., B OURDA, E., ROSL, F., and ALONSO, A. (1996). Genomic cloning and characterization of the non-occupied allele corresponding to the integration site of HPV 16 DNA in the cervical cancer cell line SiHa. Virology 217, 33-41.
5. BERNARD, H.U., and APT, D. (1994). Transcriptional control and cell type specificity of HPV gene expression. Arch. Dermatol. 130, 210-215.
6. BERRIDGE, M.V., and TAN, A.S. (1993). Characterization of the cellular reduction of 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): Subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303, 474.
7. BOSHART, M., GISSMANN, L., IKENBERG, H., KLEINHEINZ, A., SCHEURLEN, W., and ZUR HAUSEN, H.A. (1984). A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 3, 1151-1157.
8. BOUVARD, V., STOREY, A., PIM, D., and BANKS, L. (1994). Characterization of the human papillomavirus E2 protein: Evidence of trans-acfivation and trans-repression in cervical keratinocytes. EMBO J. 13, 5451-5459.
9. BROKER, T.R., CHOW, L.T., CHIN, M.T., RHODES, C.R., WOLINSKY, S.M., WHITBECK, A., and STOLER, M.H. (1989). A molecular portrait of human papillomavirus carcinogenesis. In Cancer Cells 7: Molecular Diagnostics of Hurnan Cancer. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY) pp. 197-208.
10. CHEN, Z., STORTHZ, K.A., and SHILLITOE, E.J. (1997). Mutations in the long control region of human papillomavirus DNA in oral cancer cells, and their functional consequences. Cancer Res. 57, 1614-1619.
11. CHONG, T., APT, D., GLOSS, B., ISA, M., and BERNARD, H.U. (1991). The enhancer of human papilloma-virus type 16: Binding sites for the ubiquitous transcription factors oct-l, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription. J. Virol. 65, 5933-5943.
12. CRIPE, T.P., HAUGEN, T.H., TURK, J.P., TABATABAI, F., SCHMID, P.G., III, DUERST, M., GISSMANN, L., ROMAN, A., and TUREK, L.P. (1987). Transcriptional regulation of the human papillomavirus-16 E6-E7 promoter by a keratinocyte-dependent enhancer, and by viral E2 trans-acfivator and repressor gene products: Implications for cervical carcinogenesis. EMBO J. 6, 3745.
13. CRIPE, T.P., ALDERBORN, A., ANDERSON, R.D., PARKKINEN, S., PARKKINEN, S., BERGMAN, P., HAUGEN, T.H., PETTERSSON, U., and TUREK, L.P. (1990). Transcriptional activation of the human papillomavirus-16 P97 promoter by an 88-nucleotide enhancer containing distinct cell-dependent and AP-l-responsive modules. New Biol. 2, 450-463.
14. EL AWADY, M.K., KAPLAN, J.B., O'BRIEN, S.J., and BURK, R.D. (1987). Molecular analysis of integrated human papillomavirusl6 sequences in the cervical cancer cell line SiHa. Virology 159, 389-398.
15. ELSHAMI, A.A., SAAVEDRA, A., ZHANG, H., KUCHARCZUK, J.C., SPRAY, D.C., FISHMAN, G.I., AMIN, K.M., KAISER, L.R., and ALBELDA, S.M. (1996). Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 3, 85-92.
16. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 46, 5276-5281.
17. FRISCH, M., GLIMELIUS, B., VAN DEN BRULE, A.J., WOHLFAHRT, MEIJER, C.J., WALBOOMERS, J.M., GOLDMAN, S., SVENSSON, C., ADAMI, H.O., and MELBYE, M. (1997). Sexually transmitted infection as a cause of anal cancer. N. Engl. J. Med. 337, 1350-1358.
18. GAGANDEEP, S., BREW, R., GREEN, B., CHRISTMAS, S.E., KLATZMANN, D., POSTON, G.J., and KINSELLA, A.R. (1996). Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect". Cancer Gene Ther. 3, 83-88.
19. GORCZYCA, W., GONG, J., and DARZYNKIEWICZ, Z. (1993). Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translational assays. Cancer Res. 53, 1945-1951.
20. GOUGH, M.J., MELCHER, A.A., AHMED, A., CRITTENDEN, M.R., RIDDLE, D.S., LINARDAKIS, E., RUCHATZ, A.N., EMILIUSEN, L.M., and VILE, R.G. (2001). Macrophages orchestrate the immune response to tumor cell death. Cancer Res. 61, 7240-7247.
21. HAMEL, W., MAGNELLI, L., CHIARUGI, V.P., and ISRAEL, M.A. (1996). Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 56, 2697-2702.
22. HARRIS, S.F., and BOTCHAN, M.R. (1999). Crystal structure of the human papillomavirus type 18 E2 activation domain. Science 284, 1673.
23. HIROCHIKA, H., BROKER, T.R., and CHOW, L.T. (1987). Enhancers and trans-acting E2 transcriptional factors of papillomaviruses. J. Virol. 61, 2599-2606.
24. HIROCHIKA, H., HIROCHIKA, R., BROKER, T.R., and CHOW, L.T. (1988). Functional mapping of the human papillomavirus type 11 transcriptional enhancer and its interaction with the trans-acting E2 proteins. Genes Dev. 2, 54-67.
25. HYDE, S.C., SOUTHERN, K.W., GILEADI, U., FITZJOHN, E.M., MOFFORD, K.A., WADDELL, B.E., GOOI, H.C., GODDARD, C.A., HANNAVY, K., SMYTH, S.E., EGAN, J.J., SORGI, F.L., HUANG, L., CUTHBERT, A.W., EVANS, M.J., COLLEDGE, W.H., HIGGINS, C.F., WEBB, A.K., and GILL, D.R. (2000). Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 7, 1156-1165.
26. KIVIAT, N.B., CRITCHLOW, C.W., HOLMES, K.K., KUYPERS, J., SAYER, J., DUNPHY, C., SURAWICZ, C., KIRBY, P., WOOD, R., and DALING, J.R. (1993). Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection in homosexual men. AIDS 7, 43-49.
27. MAIMAN, M. (1998). Management of cervical neoplasia in human immunodeficiency virus-infected women. J. Natl. Cancer Inst. Monogr. 23, 43-49.
28. MAIMAN, M., FRUCHTER, R.G., SERUR, E., LEVINE, P.A., ARRASTIA, C.D., and SEDLIS, A. (1993). Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. Obstet. Gynecol. 82, 170-174.
29. MAITLAND, N.J., CONWAY, N.S., WILKINSON, J., RAMSDALE, J.R., MORRIS, C.M., SANDERS, J.E., BURNS, J.E., STERN, P.L., and WELLS, M. (1992). Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. J. Pathol. 186, 275-280.
30. MARCEL, T., and GRAUSZ, J.D. (1997). The TMC worldwide gene therapy enrolment report, end 1996. Hum. Gene Ther. 8, 775-800.
31. McBRIDE, A.A., ROMANCZUK, H., and HOWLEY, P.M. (1991). The papillomavirus E2 regulatory proteins. J. Biol. Chem. 266, 18411-18414.
32. MEISSNER, J.D. (1999). Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines. J. Gen. Virol. 80, 1725-1733.
33. MOOLTEN, F.L. (1994). Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1, 279-287.
34. MULLEN, C.A. (1994). Metabolic suicide genes in gene therapy. Pharmacol. Ther. 63, 199-207.
35. NISHIHARA, E., NAGAYAMA, Y., NARIMATSU, M., NAMBA, H., WATANBE, M., NIWA, M., and YAMASHITA, S. (1998). Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro. Anticancer Res. 18, 1521-1526.
36. PALEFSKY, J.M. (1994). Anal human papillomavirus infection and anal cancer in HIV-positive individuals: An emerging problem. AIDS 8, 238-295.
37. PALEFSKY, J.M. (1995). Human papillomavirus-associated malignancies in HIV-positive men and women. Curr. Opin. Oncol. 7, 437-441.
38. PALEFSKY, J.M. (1998). Human papillomavirus infection and anogenital neoplasia in human immunodeficiency virus-positive men and women. J. Natl. Cancer Inst. Monogr. 23, 15-20.
39. PALEFSKY, J.M, HOLLY, E.A., RALSTON, M.L., ARTHUR, S.P., JAY, N., BERRY, J.M., DACOSTA, M.M., BOTFS, R., and DARRAGH, T.M. (1998a). Anal squamous intraepithelial lesions in HIVpositive and HIV-negative homosexual and bisexual men: Prevalence and risk factors. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17, 320-326.
40. PALEFSKY, J.M., HOLLY, E.A., RALSTON, M.L., JAY, N., BERRY, J.M., and DARRAGH, T.M. (1998b). High incidence of anal high-grade squamous intra-epithelial lesions among HIV-posirive and HIV-negative homosexual and bisexual men. AIDS 12, 495-503.
41. PARKER, J.N., ZHAO, W., ASKINS, K.J., BROKER, T.R., and CHOW, L.T. (1997). Mutational analyses of differentiation-dependent human papillomavirus type 18 enhancer elements in epithelial raft cultures of neonatal foreskin keratinocytes. Cell Growth Differ. 8, 751-762.
42. PATTILLO, R.A., HUSSA, R.O., STORY, M.T., RUCKERT, A.C., SHALABY, M.R., and MATTINGLY, R.F. (1977). Tumor antigen and human chorionic gonadotropin in CaSki cells: A new epidermoid cervical cancer cell line. Science 196, 1456-1458.
43. REIMER, D.L., KONG, S., MONCK, M., WYLES, J., TAM, P., WASAN, E.K., and BALLY, M.B. (1999). Liposomal lipid and plasmid DNA delivery to B16/BL6 tumors after intraperitoneal administration of cationic liposome DNA aggregates. J. Pharmacol. Exp. Ther. 289, 807-815.
44. RUBSAM, L.Z., DAVIDSON, B.L., and SHEWACH, D.S. (1998). Superior cytotoxicity with ganciclovir compared with acyclovir and 1-β-o-arabinofuranosylthymine in herpes simples virus-thymidine kinase-expressing cells: A novel paradigm for cell killing. Cancer Res. 58, 3873-3882.
45. SAWAMURA, D., MENG, X., INA, S., NAKANO, H., TAMAI, K., NOMURA, K., HANADA, K., MIYAZAKI, J., and HASHIMOTO, I. (1999). Promoter/enhancer cassettes for keratinocytes gene therapy. J. Invest. Dermatol. 112, 829-830.
46. SCHWARZ, E., FREESE, U.K., GISSMAN, L., MAYER, W., ROGGENBUCK, B., STREMLAU, A., and ZUR HAUSEN, H. (1985). Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314, 111.
47. SEEDORF, K., KRAEMMER, G., DUERST, M., SUHAI, S., and ROEWEKAMP, W.G. (1985). Human papillomavirus type 16 DNA sequence. Virology 145, 181-185.
48. SHERMAN, L., and ALLOUL, L. (1992). Human papillomavims type 16 expresses a variety of alternatively spliced mRNAs putatively encoding the E2 protein. Virology 191, 953-959.
49. SHERMAN, L., ALLOUL, N., GOLAN, I., DURST, M., and BARAM, A. (1992). Expression and splicing patterns of human papillomavims type-16 mRNAs in pre-cancerous lesions and carcinomas of the cervix, in human keratinocytes immortalized by HPV16, and in cell lines established from cervical cancers. Int. J. Cancer 50, 356-364.
50. STOLER, M.H., RHODES, C.R., WHITBECK, A., WOLINSKY, S.M., CHOW, L.T., and BROKER, T.R. (1992). Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol. 23, 117-128.
51. TAKAKUWA, K., FUJITA, K., KIKUCHI, A., SUGAYA, S., YAHATA, T., AIDA, H., KURABAYASHI, T., HASEGAWA, I., and TANAKA, K. (1997). Direct intratumoral gene transfer of the herpes simplex virus thymidine kinase gene with DNA-liposome complexes: Growth inhibition of tumors and lack of localization in normal tissues. Jpn. J. Cancer Res. 88, 166-175.
52. TODRYK, S.M., MELCHER, A.A., DALGEISH, A.G., and VILE, R.G. (2000). Heat shock proteins refine the danger theory. Immunology 99, 334-337.
53. WALBOOMERS, J.M., JACOBS, M.V., MANOS, M.M., BOSCH, F.X., KUMMER, J.A., SHAH, K.V., SNIJDERS, P.J., PETO, J., MEIJER, C.J., and Muñoz, N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19.
54. YAZAWA, K., FISHER, W.E., and BRUNICARDI, F.C. (2002). Current progress in suicide gene therapy for cancer. World J. Surg. 26, 783-789.
55. ZUR HAUSEN, H. (1991). Human papillomavimses in the pathogenesis of anogenital cancer. Virology 184, 9-13.